Experimental mRNA Vaccine Reported to Cut Melanoma Recurrence Risk by 42%

An experimental mRNA-based vaccine was reported to reduce the risk of melanoma recurrence by 42%, according to news coverage on October 22. The report offers a positive counterpoint to recent oncology setbacks for mRNA platforms. Details of trial design and endpoints were not available in the feed summary.